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THE BAYESIAN APPROACH FOR PERFORMANCE-BASED PRICING: A 
CASE STUDY IN JAPAN
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OBJECTIVES: To present a case study of Bayesian approach to performance-based 
pricing in Japan, and to discuss advantages and limitations of the proposed method. 
METHODS: The ofﬁ cial price of any new drug listed on the National Reimbursement 
List in Japan is initially determined by Ministry of Health, Labor, and Welfare in 
political manners with some equations historically developed without considering the 
science of pharmacoeconomics. The initial price determined when approved is bien-
nially re-priced downward regarding the average market price (AMP) in reality. At 
ﬁ rst, we reviewed the pricing and re-pricing methods of the government, then identiﬁ ed 
which portion of the current rules for pricing and re-pricing could be reworded with 
the quantitative methods of biostatistics and pharmacoeconomics, and ﬁ nally tried to 
develop a Bayesian method for making the current re-pricing rule better quantiﬁ ed 
incorporating performance and value of a drug. RESULTS: We identiﬁ ed three por-
tions such as premium rule in pricing, an adjustment in re-pricing, and the market 
extension premium in re-pricing could be objectively described by scientiﬁ c methods. 
We developed in theory: 1) a pharmacoeconomic method associating the premium in 
pricing with ICER (incremental cost-effectiveness ratio); 2) a Bayesian method quan-
tifying an adjustment in the current re-pricing rule with respect to estimating the AMP 
according to the degree of Bayesian belief; and 3) a mixture method of Bayes and 
ICER quantifying the market extension in re-pricing to incorporate the performance-
based concept. CONCLUSIONS: The Japanese pricing and re-pricing rules, which 
employs the performance-based concept in a subjective manner, could be improved in 
terms of pharmacoeconomics and Bayesian statistics. Although the validation of the 
theory including data availability is left for further investigation, our approach would 
be thought-provoking for any country which considers a statistical approach to poli-
cymaking for performance-based pricing or reimbursement.
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QUALITATIVE RESEARCH APPROACH
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OBJECTIVES: The number of risk-sharing schemes in the UK increased signiﬁ cantly 
since the introduction of the new Pharma Pricing and Regulation Scheme (PPRS) in 
early 2009. Other health-care systems seem to follow. The objective is to investigate 
via qualitative research if payers in Germany and The Netherlands are inﬂ uenced by 
UK decisions, if there are any preferred schemes, e.g., ﬁ nance-based versus value-
based, and if the outcome for payers and manufacturers are comparable among the 
countries concerned. METHODS: A comprehensive questionnaire was designed, vali-
dated, and translated into German and Dutch. Decision-makers at various levels 
involved in the implementation of risk-sharing models in Germany and The Nether-
lands were interviewed face to face. The interviews lasted approximately 60 minutes 
and were held in their mother language. All interviews were recorded and a total of 
n = 10 interviews were conducted. RESULTS: German payers especially sick funds 
seem to be more open to adopt risk-sharing models than their colleagues in The 
Netherlands. There is a clear tendency in both countries that UK risk-sharing schemes 
have an inﬂ uence on the decision-making process; however, most payers responded 
that there must be some adaptations to local needs. CONCLUSIONS: Risk-sharing 
models will become increasingly popular in the near future especially in Germany. 
Companies have to be prepared especially in therapeutic areas like oncology to follow 
this route as a way of market access. Although risk-sharing models have been intro-
duced in other European countries before 2009, the UK models seem to represent a 
benchmark among payers especially with regard to their transparency. 
PODIUM SESSION II: ADHERENCE AND COMPLIANCE STUDIES
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OBJECTIVES: Schizophrenia is a major psychotic disorder that has devastating effects 
on the lives of patients and their caregivers. Poor adherence to antipsychotic treatment 
is a well-recognized challenge among patients with schizophrenia and is associated 
with increased morbidity and consumption of health-care resources. Implementation 
of innovative strategies to enhance adherence is needed. To evaluate the effect of daily 
short message service (SMS) reminders on patients’ adherence to antipsychotic treat-
ment in schizophrenia. METHODS: A multicenter, randomized, open-label, con-
trolled trial. The study included clinically stabilized schizophrenic outpatients with 
adherence problems (at least one afﬁ rmative answer of Morisky–Green question-
naire—MAQ). Participants were randomized to receive a daily SMS reminder on their 
cell phone to take their medication in the following 3 months or current standard of 
care. The SMS reminder was sent daily at 10 am or 2 pm according to participants’ 
preferences. The primary end point was the absolute difference in mean adherence 
rate between the two groups after 3 months using MAQ. RESULTS: A total of 254 
patients were analyzed, 66.5% men. Mean age: 39.7 years (SD = 11.03). Baseline 
sociodemographic and clinical characteristics were similar between the two groups. 
No signiﬁ cant differences in baseline mean MAQ score were observed between groups 
(2.23, SD = 0.94 and 2.23, SD = 0.85, respectively). At month 3, mean MAQ score 
in the intervention group was 1.2 and 1.53 in the control group. The absolute differ-
ence in mean adherence rate between groups was −0.33 (95% CI −0.62, −0.03; P = 
0.03). Largest change from baseline was observed in question 4 of the questionnaire 
“When you feel better, do you sometimes stop taking your medicine?” (percentage of 
afﬁ rmative answers in the SMS group vs. control was 45% and 59%, respectively, P 
= 0.02). CONCLUSIONS: SMS reminders may help many patients become sufﬁ ciently 
adherent to their antipsychotic medication in addition to standard interventions for 
schizophrenia control.
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THE SOCIETAL BURDEN OF POOR PERSISTENCE TO TREATMENT OF 
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OBJECTIVES: Poor persistence to prescribed treatment regimens is a well-documented 
health problem. The issue is of particular importance in treatment of chronic diseases, 
such as osteoporosis. The objective of this study was to estimate the annual societal 
burden of real-world persistence to treatment of osteoporosis in Sweden. a second aim 
was to estimate the monetary net beneﬁ t of improved persistence. METHODS: The 
annual societal burden was evaluated in relation to perfect persistence to a 5-year 
treatment duration and performed using a published Markov model by Ström and 
colleagues. The target population was extracted from the Swedish Prescription Reg-
ister and based on all treatment-naïve patients who started therapy of primary osteo-
porosis in Sweden during 2009. Five hypothetical interventions were investigated, with 
improvements in the persistent proportion of between 10% and 50%. RESULTS: 
Annually, a total of 1018 fractures were estimated to be caused by nonpersistence to 
treatment of osteoporosis in Sweden. These fractures resulted in a substantial waste 
of health-care resources related to morbidity (c26 million annually) and a loss, in total, 
of 771 QALYs. Using a societal willingness-to-pay for a QALY of c60,000, the total 
annual societal burden, incorporating both monetary consequences and health effects, 
was estimated at c62.76 million. Given current Swedish cost-effectiveness guidelines, 
between approximately c225 and c1130 could be spent per patient to increase persis-
tence, depending on the level of improvement (between 10% and 50%). CONCLU-
SIONS: The total annual societal burden of current, real-world persistence was 
estimated at c63 million. The estimated additional fracture-related costs associated 
with poor persistence were larger than the current total annual expenditure on all 
osteoporosis medications in Sweden. Poor persistence to treatment of osteoporosis 
should consequently be acknowledged as an important and costly health problem, and 
be taken into account when evaluating osteoporosis interventions.
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Incorporating adherence in a health-economic evaluation is challenging. a novel con-
ceptual framework was developed that captures the multidimensional aspect of adher-
ence in a health-economic model, by considering the case of pain medication in chronic 
nonmalignant pain management. a 1-year microsimulation model was built. Realistic 
dosing proﬁ les (combining dose-taking and dose-timing information) were obtained 
from electronically compiled dosing histories gathered in the Aardex/Pharmionic data-
base. Probability and timing of dosing depended on time of intake during the day, 
day of the week, whether or not a previous dosage was taken, and number of days 
on treatment. The effect of dosages taken on pain was modeled via a pharmacoki-
netic–pharmacodynamic (PK-PD) model. The PK model translated dosages taken into 
drug concentration levels. Drug concentration levels inﬂ uenced the amount of pain a 
patient experienced, quantiﬁ ed by the PD model. Quality of life (QoL) values were 
obtained by assigning a utility value to the pain intensity a patient experienced. 
Dosages taken by the patient contributed to medication costs. Work productivity 
losses due to pain exacerbations, based on a pain survey, were included. The model 
simulated 1000 unique patients to generate stable results, comparing realistic dosing 
proﬁ les with an optimal dosing proﬁ le for a four times daily (QID) regimen. The 
realistic QID regimen had 14% lower average drug concentration levels and more 
than 3.5-fold higher standard deviation in concentration levels than the optimal 
regimen. Due to lower average concentration levels and higher ﬂ uctuation, this trans-
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lated into patients experiencing 37% higher average pain intensity, an 8% decrease 
in QoL, and total additional costs of ~$1277 annually. This study provided a concep-
tual framework to model the health-economic impact of dosing variations based on 
actual dosing information in a realistic and intuitive way. This novel concept can also 
be applied to other disease areas to assess pharmaco-economic outcomes.
AD4
THE IMPACT OF PHARMACIST INTERVENTION ON PATIENTS’ 
ADHERENCE TO ANTIDEPRESSANT MEDICATION AND PATIENT-
REPORTED OUTCOMES
Aljumah K, Donyai P
University of Reading, Reading, UK
OBJECTIVES: Medications, regardless of effectiveness, do not work in patients who 
do not take them. Poor adherence to prescribed medication regimens has been a well-
recognized problem in all of medicine and patients with chronic conditions, such as 
depression, are less likely to follow prescription orders than those with acute condi-
tions. In depression, several studies have reported a medication adherence rate of 
about 72% within the ﬁ rst month of treatment which drops sharply to about 43% 
after 6 months of treatment. Pharmacists may be able to help improve adherence rates, 
yet no single review has examined the impact of pharmacist interventions on adherence 
to antidepressants. The aim of this study was to summarize the literature and deter-
mine whether pharmacist intervention will 1) improve adherence in depression; and 
2) improve patient-reported outcomes (PRO). METHODS: A systematic review of the 
literature was conducted using the PubMed database to retrieve studies examining the 
impact of pharmacist interventions on adherence to antidepressants and on patient-
reported outcomes, from 1990 to 2010. The following MESH terms were used: 
pharmacist intervention, medication intervention, depression, medication adherence, 
health-related quality of life, patient reported outcomes, and antidepressants. a total 
of 25 papers were retrieved with 11 excluded on the basis of abstract or full-text 
review resulting in 14 studies suitable for inclusion. RESULTS: The most common 
intervention strategy that pharmacists utilized was a combination of drug monitoring 
(baseline assessment and treatment follow-up), drug counseling by telephone and 
personal interviews, and patient education (about medication side effects).The results 
of these interventions were positive, improvement varying from 15% to 19%, and 
also, HRQL improved to varying degrees. CONCLUSIONS: The studies support the 
roles of pharmacists in providing interventions to improve medication adherence in 
depression. The results can provide a basis for future studies examining the cost-
effectiveness of pharmacist interventions in depression. 
PODIUM SESSION II: BIOLOGIC AGENT STUDIES AND METHODS
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COST-EFFECTIVENESS, VALUE OF INFORMATION, AND BUDGET 
IMPACT OF CERTOLIZUMAB PEGOL COMPARED TO SUBCUTANEOUS 
TUMOR NECROSIS FACTOR (TNF) INHIBITORS AND METHOTREXATE 
IN THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID 
ARTHRITIS IN FINLAND
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OBJECTIVES: To analyze the cost-effectiveness, multinomial expected value of perfect 
information (mEVPI), and budget impact of certolizumab pegol (CZP) compared to 
the used ﬁ rst-line subcutaneously administered tumor necrosis factor (TNF) − inhibi-
tors + methotrexate (MTX) and MTX alone in the treatment of moderate-to-severe 
rheumatoid arthritis (RA) in the Finnish setting. METHODS: An Excel-based, proba-
bilistic lifetime Markov cohort model was developed to assess the cost-effectiveness 
and mEVPI. Treatment efﬁ cacy was measured using the ACR-responses (no ACR20, 
ACR20, ACR50, or ACR70) at 3 months. ACR estimated response rates were based 
on adjusted indirect comparison (MTX as the common comparator) of published 
clinical trials. The health state utilities were estimated from the CZP-trials using 
regression models. The inpatient days were linked to patients’ HAQ-scores according 
to published literature. Cost estimates from Finnish sources were used and assessed 
from payer perspective. Cost and health outcomes were discounted with annual 3% 
discount rate. Undiscounted budget impact of CZP was estimated for years 2010–
2013 using Excel model. Equal inpatient costs and treatment efﬁ cacies were assumed 
for all TNF inhibitors. RESULTS: The lifetime costs for CZP + MTX, etanercept + 
MTX, and MTX alone were c179,986, c201,781, and c186,986, respectively. The 
corresponding QALYs (life-years) were 7.041 (15.697), 6.838 (15.646), and 6.336 
(15.547). According to the cost-effectiveness acceptability frontier, CZP + MTX was 
the optimal treatment option with 58% to 73% probability of being cost-effective at 
willingness-to-pay values of c0–30,000 per QALY gained. The respective mEVPI was 
c5058–3701 per patient. Based on clinical responses, CZP + MTX dominated also 
adalimumab + MTX with 100–85% probability of cost-effectiveness (c0–30,000 per 
QALY gained; EVPI c0–218 per patient). The introduction of CZP produced annual 
budgetary net savings of c0.17–0.80 million during 2010–2013 in budget impact 
analysis. CONCLUSIONS: This analysis shows that, on average, CZP + MTX domi-
nated the other subcutaneously injected TNF inhibitors considered or MTX alone in 
the Finish setting. The use of CZP resulted in budgetary net savings.
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OBJECTIVES: To conduct a Discrete Choice Experiment (DCE) to elicit rheumatoid 
arthritis (RA) patients’ preferences regarding treatment with BIOLOGIC AGENTS 
(BA). METHODS: We designed a DCE with RA patients and seven treatment attri-
butes: effectiveness, route of administration, frequency of administration, local and 
systemic adverse effects, severe infections, and out-of-pocket costs. RA patients who 
had never received BA from one private and one public hospital in Buenos Aires were 
included. a multinomial probit regression model (MNP) was used. RESULTS: A total 
of 240 RA participated (mean age 56.2 [SD 13.5], 87% women, median disease dura-
tion 9 years), all receiving conventional DMARDs (84.5% Metotrexate); median 
Clinical Disease Activity Index 7.5, and median HAQ 0.5. All the attributes showed 
to be signiﬁ cant factors affecting choice of treatment. Most attributes levels showed 
coefﬁ cients with the expected signs and were statistically signiﬁcant. Attributes impor-
tance ranking was in the following order: cost, systemic adverse events, frequency of 
administration, efﬁ cacy, route of administration, local adverse events, and serious 
infection (table). Patients had relatively high monthly WTP for treatments that signiﬁ -
cantly reduced the risk of systemic adverse events: mean 331 (95% CI: 212–499) US 
dollars ($) for a reduction from 30% to 10%; of decreasing dose frequency: mean 
$302 (95% CI: 183–461) for going from weekly to monthly administration; increasing 
treatment efﬁ cacy: mean: $386 (95% CI: 285–532) for 40 versus 20 mm reduction in 
patient global assessment VAS), and also for switching from an intravenous to an oral 
therapy: mean $262 (95% CI: 262–555). CONCLUSIONS: Different treatment attri-
butes had a signiﬁ cant and different inﬂ uence in RA patients’ choice of BA. The results 
of the DCE indicated that most respondents would be willing to pay for treatments 
that importantly reduced the risk of systemic adverse effects, dose frequency, with 
increased treatment efﬁ cacy, and with an oral route of administration.
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OBJECTIVES: Studies of orphan drugs are, by nature, confronted with small patient 
populations, meaning that randomized controlled trials (RCTs) will have limited 
statistical power. Enzyme replacement therapy (ERT) is an orphan drug for Pompe 
disease, a metabolic orphan disease, with a prevalence in the The Netherlands of 1 
per 40,000 births. In order to estimate the (cost-)effectiveness of ERT, we developed 
a disease model founded on all available clinical knowledge. METHODS: We devel-
oped a disease model with a strong clinical basis which linked disease-related factors 
with quality-adjusted life-years. The structure of the Wilson-Cleary health outcomes 
model was used as a blueprint. Based on literature and expert opinion, clinically 
relevant aspects of Pompe disease were applied to the distinct entities of the Wilson-
Cleary model. Data from a Dutch cohort study (n = 94, mean follow-up = 2.7 years) 
were used to quantify the relationships between the different entities by means of 
regression analyses. RESULTS: A conceptual model for Pompe disease was developed 
by establishing a clinically plausible pathway from enzyme activity (“biological vari-
ables” in Wilson-Cleary model) via muscle strength and respiratory function 
(“symptom status”), and MCS and PCS from the SF-36 (“functional status”) to the 
ﬁ nal entity of health utility (“quality of life” using EQ-5D and SF-6D). The strengths 
of the relationships between these entities were based on the results of the regression 
analyses. Patient characteristics such as age, gender, and disease duration affected all 
entities in the model. Therapy was assumed to affect only enzyme activity in the model; 
all other health outcomes could only be affected via an impact on enzyme activity. 
CONCLUSION: We have developed a clinically based model to assess the long-term 
cost-effectiveness of ERT in Pompe disease. The approach used here is expected to be 
applicable in the assessment of other orphan drugs.
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OBJECTIVES: Owing to rapid, persistent efﬁ cacy in reducing pain and preventing 
structural damage, tumor necrosis factor-alpha inhibitors (anti-TNFs) has revolution-
ized the treatment of ankylosing spondylitis (AS). However, the high price of anti-
TNFs has limited their use. Recent studies suggest that increased medication costs by 
adopting anti-TNFs may be offset by decreased values of other cost categories. In most 
cost-effectiveness studies on AS treatments, costs were estimated as a whole. Our 
